Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
06:40:59 EDT Sat 02 Aug 2025
Enter Symbol
or Name
USA
CA



Z:NNVC - NANOVIRICIDES INC - http://www.nanoviricides.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
NNVC - Z0.11.43·2.400.41.58-0.028-1.7179.52663431.60  1.62  1.562.34  0.942518:24:12Jul 3015 min RT 2¢

Recent Trades - Last 10 of 343
Time ETExPriceChangeVolume
18:24:12Z1.57-0.0550
18:16:25Z1.62 50
18:06:44Z1.62 100
17:37:39Z1.62 600
17:05:20Z1.61-0.015
17:03:39Z1.61-0.015
16:10:03Z1.58-0.041
16:10:03Z1.58-0.041
16:04:15Z1.58-0.041
16:04:15Z1.58-0.041

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-07-30 08:30U:NNVCNews ReleaseMeasles Cases Increasing Worldwide, Need the New NV-387 Broad-Spectrum Antiviral to Combat, Says NanoViricides
2025-07-23 08:30U:NNVCNews ReleaseNanoViricides Discusses the Multi-Billion-Dollar Potential of Its Broad-Spectrum Drug NV-387; Its Effectiveness Against Influenza, Coronaviruses, RSV, MPox and Now Measles Expected to Drive Value
2025-07-21 06:30U:NNVCNews ReleaseMeasles Now Has a Drug - NV-387 Broad-Spectrum Antiviral Successful in Animal Studies, says NanoViricides
2025-07-16 08:30U:NNVCNews ReleaseWHO Extended Global Emergency Status of MPox Epidemic - Development of Treatment for MPox with NV-387 is Timely, Says NanoViricides
2025-07-14 06:30U:NNVCNews ReleaseAdaptive Clinical Protocol Design for Phase II MPox Clade I Treatment with a Novel Broad-Spectrum Drug NV-387 is Almost Complete, Reports NanoViricides
2025-07-01 06:41U:NNVCNews ReleaseThere is a Strong Business Case for Phase II Clinical Program for Treatment of MPox Infection Using NV-387, an Industry-Leading Broad-Spectrum Antiviral Drug Candidate
2025-06-18 06:30U:NNVCNews ReleaseWith Rising Variants of COVID and Bird Flu, the Single Broad-Spectrum Antiviral NV-387 Would be the Best Partner for Preparedness, Says NanoViricides' Dr. Diwan
2025-06-04 06:55U:NNVCNews ReleaseNanoViricides Measles Drug Development Animal Study is Imminent
2025-05-28 06:31U:NNVCNews ReleaseNanoViricides to Present at the BIO International Convention in Boston on Monday, June 16, 2025
2025-05-22 06:31U:NNVCNews ReleaseThe New Rational FDA COVID Vaccine Policy is Long Overdue, Says NanoViricides' Dr. Diwan
2025-05-16 06:31U:NNVCNews ReleaseNanoViricides, Inc. Has Filed its Quarterly Report: Broad-Spectrum Antiviral NV-387 To Combat MPox Pandemic in Africa - Phase II Clinical Trial Update, Also Readying to Combat Measles Outbreaks, and to Tackle Bird Flu
2025-05-14 06:31U:NNVCNews ReleaseMeasles Cases Are Increasing Globally; MPox Continues to Be a Threat - Broad-Spectrum Antiviral Drug Could Be the Solution
2025-05-08 06:31U:NNVCNews ReleaseBroad-Spectrum Antiviral Drug NV-387 Cleared for Phase II Clinical Trial Application by the National Ethics Committee of the Democratic Republic of Congo
2025-05-05 06:31U:NNVCNews ReleaseNanoViricides, Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference, May 14th, NYC
2025-04-29 06:31U:NNVCNews ReleaseMeasles is Likely to Become Endemic - NanoViricides Is Testing a Drug to Combat It
2025-04-14 06:32U:NNVCNews ReleaseMeasles Outbreak Expands Begging for a Drug to Treat the Infection - NanoViricides Declares it is Ready to Fight the Outbreak
2025-03-11 06:31U:NNVCNews ReleaseNanoViricides Not Affected by Tariffs and Other Policies, Has Excellent Long Term Outlook, Stock-Price Decline Misguided, Explains the Company
2025-03-04 06:32U:NNVCNews ReleaseMeasles Outbreak: NV-387 Promises To Be An Effective Drug To Treat Patients; We are Ready To Work With HHS, Says NanoViricides President Dr. Anil Diwan
2025-02-19 06:31U:NNVCNews ReleaseNanoViricides, Inc. Has Filed its Quarterly Report
2025-02-11 06:32U:NNVCNews ReleaseNanoViricides Drug Can Fight Bird Flu Pandemic; H5N1 Virus Cannot Escape